Biomarkers in cancer immunotherapy

Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay syst...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Cancer cell Ročník 27; číslo 1; s. 12
Hlavní autori: Schumacher, Ton N, Kesmir, Can, van Buuren, Marit M
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 12.01.2015
Predmet:
Antibodies, Neoplasm - therapeutic use
Biomarkers, Tumor - genetics
Biomarkers, Tumor - immunology
Humans
Immunotherapy - methods
Neoplasms - genetics
Neoplasms - immunology
T-Lymphocytes - immunology
ISSN:1878-3686, 1878-3686
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer-immunity cycle.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1878-3686
1878-3686
DOI:10.1016/j.ccell.2014.12.004